Rajan Khanna, MD
Internal Medicine · Shreveport, LANPI 1770581225
Payments from drug & device makers
Across 359 payments — averaging $163.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$34K
- AbbVie$5K
- AstraZeneca$5K
- Amgen$3K
- Lilly USA, LLC$1K
- Paratek Pharmaceuticals, Inc.$1K
- plus $9K from 34 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 15 | $33,946 |
| AbbVie(2 entities) | 12 | $5,306 |
| AstraZeneca | 72 | $5,002 |
| Amgen | 45 | $2,676 |
| Lilly USA, LLC | 34 | $1,489 |
| Paratek Pharmaceuticals, Inc. | 19 | $1,477 |
| Sanofi-aventis U.S. LLC | 10 | $1,293 |
| Bayer | 15 | $736 |
| Novo Nordisk | 18 | $730 |
| Merck | 14 | $681 |
| Johnson & Johnson | 8 | $412 |
| Amarin Pharma, Inc. | 3 | $375 |
| Daiichi Sankyo Inc. | 3 | $375 |
| Sumitomo Pharma America, Inc. | 18 | $368 |
| Melinta Therapeutics, LLC | 4 | $346 |
| Astellas Pharma US Inc | 12 | $257 |
| Otsuka America Pharmaceutical, Inc. | 5 | $255 |
| Evoke Pharma, Inc. | 2 | $250 |
| Gilead | 2 | $250 |
| Phathom Pharmaceuticals, Inc. | 2 | $244 |
| Neurocrine Biosciences, Inc. | 2 | $240 |
| Abbott | 4 | $194 |
| Pfizer | 5 | $193 |
| Kowa Pharmaceuticals America, Inc. | 9 | $172 |
| Globus Medical | 1 | $171 |
| Recor Medical Inc | 1 | $147 |
| Ferring Pharmaceuticals Inc. | 1 | $129 |
| Shionogi Inc | 1 | $125 |
| Urovant Sciences Inc | 1 | $125 |
| Actelion Pharmaceuticals US, Inc. | 1 | $125 |
| Insmed, Inc. | 1 | $125 |
| Mannkind Corporation | 1 | $124 |
| Ardelyx, Inc. | 1 | $122 |
| Boehringer Ingelheim | 5 | $92 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $78 |
| Sunovion Pharmaceuticals Inc. | 2 | $61 |
| Exelixis Inc. | 1 | $48 |
| Novartis | 3 | $48 |
| Exact Sciences | 3 | $46 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$58,845 in reported general payments places this provider in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Shreveport
- Deepika RallaShreveport$261K
- Maliha AgloriaShreveport$181K
- Bharat SachdevaShreveport$165K
- Ishak MansiShreveport$53K
- Wendell WallShreveport$25K
- Attila BaloghShreveport$18K
- Ammar AlqaidShreveport$18K
- William SmithNew Orleans$50.5M
- Robert JeanfreauMetairie$13.4M
- Katherine PearceBaton Rouge$12M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.